Yael Weiss completed her MD PhD at Hadassah Medical School at the Hebrew University in Jerusalem. She has over 20 years of industry experience in medical/clinical and business development roles at Genzyme, Merck and Ultragenyx. Yael founded Mahzi Therapeutics in 2020 to bring therapies to patients with underdiagnosed ultra rare genetic neurodevelopmental disorders. Mahzi works closely with patient foundations to support their journey towards drug development and bring programs into Mahzi once pre-clinical proof of concept is established.

Yael is a member of the NIH driven Bespoke Gene Therapy (BCTG) consortium, ASGCT translational committee, N=1 collaborative and a 2022 Termeer Fellow. Board member/advisor to ADNP and FOXG1 foundations.